Antibiotic Management of Methicillin-Resistant Staphylococcus aureus–Associated Acute Pulmonary Exacerbations in Cystic Fibrosis

Annals of Pharmacotherapy

Volumn 49, Issue 4, 2015, Pages 458-468

  Fusco, Nicholas M ^a   Toussaint, Kimberly A ^b   Prescott, William Allan ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

anti infective agents; cystic fibrosis; infection; methicillin resistant Staphylococcus aureus

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; LINEZOLID; MINOCYCLINE; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ACUTE PULMONARY EXACERBATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CASE STUDY; COCHRANE LIBRARY; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; LUNG FIBROSIS; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; CYSTIC FIBROSIS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; LINEZOLID; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84924859282     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014567526     Document Type: Review

References (105)

1. Bhatt JM.Treatment of pulmonary exacerbations in cystic fibrosis.Eur Respir Rev. 2013;22:205-216
2. Flume PA,Mogayzel PJ,Robinson KA, et al.Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.Am J Respir Crit Care Med. 2009;180:802-808
3. Doring G,Flume P,Heijerman H, et al.Treatment of lung infection in patients with cystic fibrosis: current and future strategies.J Cyst Fibros. 2012;11:461-479
4. Parkins MD,Elborn JS.Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.J Antimicrob Chemother. 2010;65:1853-1861
5. Dasenbrook EC,Checkley W,Merlo CA,Konstan MW,Lechtzin N,Boyle MP.Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.JAMA. 2010;303:2386-2392
6. Patient Registry. Cystic Fibrosis Foundation, 2012. http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf. Access October 1, 2014.
7. Kahl BC.Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease.Int J Med Microbiol. 2010;300:514-519
8. Dasenbrook EC,Merlo CA,Diener-West M,Lechtzin N,Boyle MP.Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.Am J Respir Crit Care Med. 2008;178:814-821
9. Ren CL,Morgan WJ,Konstan MW, et al.Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function.Pediatr Pulmonol. 2007;42:513-518
10. Vanderhelst E,De Meirleir L,Verbanck S,Pierard D,Vincken W,Malfroot A.Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis: a single-center, case control study of 165 patients.J Cyst Fibros. 2012;11:2-7
11. Cox DW,Kelly C,Rush R,O’Sullivan N,Canny G,Linnane B.The impact of MRSA infection in the airways of children with cystic fibrosis; a case-control study.Ir Med J. 2011;104:305-308
12. Gangell C,Gard S,Douglas T, et al.Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis.Clin Infect Dis. 2011;53:425-432
13. Sagel SD,Gibson RL,Emerson J, et al.Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.J Pediatr. 2009;154:183-188
14. Wolter DJ,Emerson JC,McNamara S, et al.Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.Clin Infect Dis. 2013;57:384-391
15. Flume PA,O’Sullivan BP,Robinson KA, et al.Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.Am J Respir Crit Care Med. 2007;176:957-969
16. Szaff M,Hoiby N,Flensborg EW.Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.Acta Paediatr Scand. 1983;72:651-657
17. Zobell JT,Young DC,Hatch M, et al.Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients.Pediatr Pulmonol. 2013;48:311
18. Stone A,Saiman L.Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis.Curr Opin Pulm Med. 2007;13:515-521
19. Cakir Aktas N,Erturan Z,Karatuna O,Karahasan Yagci A.Panton-Valentine leukocidin and biofilm production of Staphylococcus aureus isolated from respiratory tract.J Infect Dev Ctries. 2013;7:888-891
20. Besier S,Smaczny C,von Mallinckrodt C, et al.Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.J Clin Microbiol. 2007;45:168-172
21. Stone A,Quittell L,Zhou J, et al.Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts.Pediatr Infect Dis J. 2009;28:895-899
22. Elizur A,Orscheln RC,Ferkol TW, et al.Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis.Chest. 2007;131:1718-1725
23. Nadesalingam K,Conway SP,Denton M.Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.J Cyst Fibros. 2005;4:49-52
24. Chmiel JF,Aksamit TR,Chotirmall SH, et al.Antibiotic management of lung infections in cystic fibrosis: I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.Ann Am Thorac Soc. 2014;11:1120-1129
25. Lamer C,de Beco V,Soler P, et al.Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.Antimicrob Agents Chemother. 1993;37:281-286
26. Goss CH,Muhlebach MS.Review: Staphylococcus aureus and MRSA in cystic fibrosis.J Cyst Fibros. 2011;10:298-306
27. van Hal SJ,Lodise TP,Paterson DL.The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Clin Infect Dis. 2012;54:755-771
28. Cafiso V,Bertuccio T,Spina D, et al.Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients.Eur J Clin Microbiol Infect Dis. 2010;29:1277-1285
29. Filleron A,Chiron R,Reverdy ME, et al.Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients.J Cyst Fibros. 2011;10:377-382
30. Rybak MJ,Lomaestro BM,Rotschafer JC, et al.Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Pharmacotherapy. 2009;29:1275-1279
31. Patel N,Pai MP,Rodvold KA,Lomaestro B,Drusano GL,Lodise TP.Vancomycin: we can’t get there from here.Clin Infect Dis. 2011;52:969-974
32. Pleasants RA,Michalets EL,Williams DM,Samuelson WM,Rehm JR,Knowles MR.Pharmacokinetics of vancomycin in adult cystic fibrosis patients.Antimicrob Agents Chemother. 1996;40:186-190
33. Stockmann C,Sherwin CM,Zobell JT, et al.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Pharmacotherapy. 2013;33:1288-1296
34. Fung L.Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.Ann Pharmacother. 2012;46:e26
35. Liu C,Bayer A,Cosgrove SE, et al.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.Clin Infect Dis. 2011;52:285-292
36. Jung YJ,Koh Y,Hong SB, et al.Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia.Crit Care Med. 2010;38:175-180
37. Tremblay S,Lau TT,Ensom MH.Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?.Ann Pharmacother. 2013;47:1045-1054
38. Cambridge, MA: Vertex Pharmaceuticals Inc; 2012:
39. Sinclair EA,Yenokyan G,McMunn A,Fadrowski JJ,Milstone AM,Lee CK.Factors associated with acute kidney injury in children receiving vancomycin.Ann Pharmacother. 2014;48:1555-1562
40. Boselli E,Breilh D,Rimmele T, et al.Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.Crit Care Med. 2005;33:1529-1533
41. Conte JE,Golden JA,Kipps J,Zurlinden E.Intrapulmonary pharmacokinetics of linezolid.Antimicrob Agents Chemother. 2002;46:1475-1480
42. Gales AC,Sader HS,Andrade SS,Lutz L,Machado A,Barth AL.Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.Int J Antimicrob Agents. 2006;27:300-302
43. Hill RL,Kearns AM,Nash J, et al.Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.J Antimicrob Chemother. 2010;65:442-445
44. Roman F,Roldan C,Trincado P,Ballesteros C,Carazo C,Vindel A.Detection of linezolid-resistant Staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain.Antimicrob Agents Chemother. 2013;57:2428-2429
45. Tazi A,Chapron J,Touak G, et al.Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.Antimicrob Agents Chemother. 2013;57:5186-5188
46. Endimiani A,Blackford M,Dasenbrook EC, et al.Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.Antimicrob Agents Chemother. 2011;55:1684-1692
47. Saralaya D,Peckham DG,Hulme B, et al.Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.J Antimicrob Chemother. 2004;53:325-328
48. Bosso JA,Flume PA,Gray SL.Linezolid pharmacokinetics in adult patients with cystic fibrosis.Antimicrob Agents Chemother. 2004;48:281-284
49. Andes D,van Ogtrop ML,Peng J,Craig WA.In vivo pharmacodynamics of a new oxazolidinone (linezolid).Antimicrob Agents Chemother. 2002;46:3484-3489
50. Rayner CR,Forrest A,Meagher AK,Birmingham MC,Schentag JJ.Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.Clin Pharmacokinet. 2003;42:1411-1423
51. Keel RA,Schaeftlein A,Kloft C, et al.Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.Antimicrob Agents Chemother. 2011;55:3393-3398
52. Beringer P,Nguyen M,Hoem N, et al.Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.Antimicrob Agents Chemother. 2005;49:3676-3681
53. Chiappini E,Conti C,Galli L,de Martino M.Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review.Clin Ther. 2010;32:66-88
54. Santos RP,Prestidge CB,Brown ME, et al.Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.Pediatr Pulmonol. 2009;44:148-154
55. Ferrin M,Zuckerman JB,Meagher A,Blumberg EA.Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis.Pediatr Pulmonol. 2002;33:221-223
56. Serisier DJ,Jones G,Carroll M.Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid.J Cyst Fibros. 2004;3:61
57. Rubinstein E,Cammarata S,Oliphant T,Wunderink R.Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.Clin Infect Dis. 2001;32:402-412
58. Wunderink RG,Cammarata SK,Oliphant TH,Kollef MH.Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.Clin Ther. 2003;25:980-992
59. New York, NY: Pfizer; 2014:
60. Huang V,Gortney JS.Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists.Pharmacotherapy. 2006;26:1784-1793
61. Nambiar S,Rellosa N,Wassel RT,Borders-Hemphill V,Bradley JS.Linezolid-associated peripheral and optic neuropathy in children.Pediatrics. 2011;127:e1528-e1532
62. Beringer PM,Owens H,Nguyen A,Benitez D,Rao A,D’Argenio DZ.Pharmacokinetics of doxycycline in adults with cystic fibrosis.Antimicrob Agents Chemother. 2012;56:70-74
63. Champion EA,Miller MB,Popowitch EB, et al.Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis.Pediatr Pulmonol. 2013;49:230-237
64. Cocchi P,Cariani L,Favari F, et al.Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview.J Cyst Fibros. 2011;10:407-411
65. Patterson PR.Minocycline in the antibiotic regimen of cystic fibrosis patients: weight gain and clinical improvement.Clin Pediatr. 1977;16:60-63
66. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med. 2005;171:388-416
67. Sanchez AR,Rogers RS,Sheridan PJ.Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity.Int J Dermatol. 2004;43:709-715
68. Reed MD,Stern RC,Bertino JS,Myers CM,Yamashita TS,Blumer JL.Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.J Pediatr. 1984;104:303-307
69. Citron DM,Tyrrell KL,Merriam CV,Goldstein EJ.In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.Antimicrob Agents Chemother. 2010;54:1627-1632
70. Ge Y,Biek D,Talbot GH,Sahm DF.In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.Antimicrob Agents Chemother. 2008;52:3398-3407
71. Polenakovik HM,Pleiman CM.Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.Int J Antimicrob Agents. 2013;42:450-455
72. Saravolatz L,Pawlak J,Johnson L.In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.Antimicrob Agents Chemother. 2010;54:3027-3030
73. File TM,Low DE,Eckburg PB, et al.Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.Clin Infect Dis. 2010;51:1395-1405
74. Vidaillac C,Leonard SN,Rybak MJ.In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.Antimicrob Agents Chemother. 2009;53:4712-4717
75. Molloy L,Snyder AH,Srivastava R,Rybak MJ,McGrath E.Ceftaroline fosamil for methicillin-resistant Staphylococcus aureus pulmonary exacerbation in a pediatric cystic fibrosis patient.J Pediatr Pharmacol Ther. 2014;19:135-140
76. Zhanel GG,Lam A,Schweizer F, et al.Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.Am J Clin Dermatol. 2008;9:245-254
77. Laohavaleeson S,Tessier PR,Nicolau DP.Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.Antimicrob Agents Chemother. 2008;52:2389-2394
78. Awad SS,Rodriguez AH,Chuang YC, et al.A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.Clin Infect Dis. 2014;:
79. Basilea Pharmaceutica. Basilea provides update on ceftopibrole’s U.S. regulatory status. http://www.basilea.com/News-and-Media/Basilea-provides-update-on-ceftobipr-oles-U-S-regulatory-status/50be69bd-f44b-0453-4ae0-7894a-0bb3e91. Published June25, 2014. Accessed October 1, 2014.
80. Hand WL,Corwin RW,Steinberg TH,Grossman GD.Uptake of antibiotics by human alveolar macrophages.Am Rev Respir Dis. 1984;129:933-937
81. Shapera RM,Warwick WJ,Matsen JM.Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis.J Pediatr. 1981;99:647-650
82. Mandell LA,Wunderink RG,Anzueto A, et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis. 2007;44:S27-S72
83. Bradley JS,Byington CL,Shah SS, et al.Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.Clin Infect Dis. 2011;53:617-630
84. Moore ZS,Jerris RC,Hilinski JA.High prevalence of inducible clindamycin resistance among Staphylococcus aureus isolates from patients with cystic fibrosis.J Cyst Fibros. 2008;7:206-269
85. Glikman D,Siegel JD,David MZ, et al.Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus.Chest. 2008;133:1381-1387
86. Guskey MT,Tsuji BT.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Pharmacotherapy. 2010;30:80-94
87. Lodise TP,Gotfried M,Barriere S,Drusano GL.Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.Antimicrob Agents Chemother. 2008;52:2300-2304
88. Gander S,Kinnaird A,Finch R.Telavancin: in vitro activity against staphylococci in a biofilm model.J Antimicrob Chemother. 2005;56:337-343
89. San Francisco, CA: Theravance, Inc; 2013:
90. Rubinstein E,Lalani T,Corey GR, et al.Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.Clin Infect Dis. 2011;52:31-40
91. Polyzos KA,Mavros MN,Vardakas KZ,Makris MC,Rafailidis PI,Falagas ME.Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.PLoS One. 2012;7:e41870
92. Florescu I,Beuran M,Dimov R, et al.Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study.J Antimicrob Chemother. 2008;62:i17-i28
93. Norskov-Lauritsen N,Marchandin H,Dowzicky MJ.Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).Int J Antimicrob Agents. 2009;34:121-130
94. Slover CM,Rodvold KA,Danziger LH.Tigecycline: a novel broad-spectrum antimicrobial.Ann Pharmacother. 2007;41:965-972
95. Conte JE,Golden JA,Kelly MG,Zurlinden E.Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.Int J Antimicrob Agents. 2005;25:523-529
96. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2010:
97. Burkhardt O,Rauch K,Kaever V,Hadem J,Kielstein JT,Welte T.Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.Int J Antimicrob Agents. 2009;34:101-102
98. Cai Y,Wang R,Liang B,Bai N,Liu Y.Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.Antimicrob Agents Chemother. 2011;55:1162-1172
99. McGovern PC,Wible M,El-Tahtawy A,Biswas P,Meyer RD.All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.Int J Antimicrob Agents. 2013;41:463-467
100. Prasad P,Sun J,Danner RL,Natanson C.Excess deaths associated with tigecycline after approval based on noninferiority trials.Clin Infect Dis. 2012;54:1699-1709
101. Tasina E,Haidich AB,Kokkali S,Arvanitidou M.Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.Lancet Infect Dis. 2011;11:834-844
102. Yahav D,Lador A,Paul M,Leibovici L.Efficacy and safety of tigecycline: a systematic review and meta-analysis.J Antimicrob Chemother. 2011;66:1963-1971
103. US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed October 1, 2014.
104. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. http://www.fda.gov/drugs/drugsafety/ucm369580.htm. Accessed October 1, 2014.
105. Wallace RJ,Dukart G,Brown-Elliott BA,Griffith DE,Scerpella EG,Marshall B.Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.J Antimicrob Chemother. 2014;69:1945-1953